Adelaide Research & Scholarship: Search

Search

Results 1-10 of 18 (Search time: 0.002 seconds).

previous
1
2
next

Item hits:

Preview	Issue Date	Title	Author(s)
	2004	Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia	Mollee, P.; Arthur, C.; Hughes, T.; Januszewicz, H.; Grigg, A.; Bradstock, K.; Wolf, M.; Gibson, J.; Schwarer, A.; Spencer, A.; Browett, P.; Hawkins, T.; Seldon, M.; Herrmann, R.; Watson, A.; Seymour, J.; Martin, N.; Shina, S.; Low, C.; Wright, S.; et al.
	2001	Integration of cytogenetic landmarks into the draft sequence of the human genome	Cheung, V.; Nowak, N.; Jang, W.; Kirsch, I.; Zhao, S.; Chen, X.; Furey, T.; Kim, U.; Kuo, W.; Olivier, M.; Conroy, J.; Kasprzyk, A.; Massa, H.; Yonescu, R.; Sait, S.; Thoreen, C.; Snijders, A.; Lemyre, E.; Bailey, J.; Bruzel, A.; et al.
	2006	Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia	Druker, B.; Guilhot, F.; O'Brien, S.; Gathmann, I.; Kantarjian, H.; Gattermann, N.; Deininger, M.; Silver, R.; Goldman, J.; Stone, R.; Cervantes, F.; Hochhaus, A.; Powell, B.; Gabrilove, J.; Rousselot, P.; Reiffers, J.; Cornelissen, J.; Hughes, T.; Agis, H.; Fischer, T.; et al.
	2002	Considerations for the safe prescribing and use of COX-2-specific inhibitors	Barraclough, D.; Bertouch, J.; Brooks, P.; Brown, M.; Cleland, L.; Clemens, L.; Crowley, S.; Day, R.; DeJager, J.; Edmonds, J.; Fletcher, P.; Franks, G.; Harris, D.; Horowitz, J.; Johnston, M.; Kerr, S.; Littlejohn, G.; MacDonald, G.; McColl, G.; Sambrook, P.; et al.
	2009	Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes	Galluzzi, L.; Aaronson, S.A.; Abrams, J.; Alnemri, E.S.; Andrews, D.W.; Baehrecke, E.H.; Bazan, N.G.; Blagosklonny, M.V.; Blomgren, K.; Borner, C.; Bredesen, D.E.; Brenner, C.; Castedo, M.; Cidlowski, J.A.; Ciechanover, A.; Cohen, G.M.; De Laurenzi, V.; De Maria, R.; Deshmukh, M.; Dynlacht, B.D.; et al.
	2008	Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia	le Coutre, P.; Ottmann, O.; Giles, F.; Kim, D.; Cortes, J.; Gattermann, N.; Apperley, J.; Larson, R.; Abruzzese, E.; O'Brien, S.; Kuliczkowski, K.; Hochhaus, A.; Mahon, F.; Saglio, G.; Gobbi, M.; Kwong, Y.; Baccarani, M.; Hughes, T.; Martinelli, G.; Radich, J.; et al.
	2008	Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group	Ryan, G.; Martinelli, G.; Kuper-Hommel, M.; Tsang, R.; Pruneri, G.; Yuen, K.; Roos, D.; Lennard, A.; Devizzi, L.; Crabb, S.; Hossfeld, D.; Pratt, G.; Dell'Olio, M.; Choo, S.; Bociek, R.; Radford, J.; Lade, S.; Gianni, A.; Zucca, E.; Cavalli, F.; et al.
	2009	A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph plus CML or relapsed/refractory Ph plus ALL	Tojo, A.; Usuki, K.; Urabe, A.; Maeda, Y.; Kobayashi, Y.; Jinnai, I.; Ohyashiki, K.; Nishimura, M.; Kawaguchi, T.; Tanaka, H.; Miyamura, K.; Miyazaki, Y.; Hughes, T.; Branford, S.; Okamoto, S.; Ishikawa, J.; Okada, M.; Usui, N.; Tanii, H.; Amagasaki, T.; et al.
	2008	Cachexia: a new definition	Evans, W.; Morley, J.; Argiles, J.; Bales, C.; Baracos, V.; Guttridge, D.; Jatoi, A.; Kalantar-Zadeh, K.; Lochs, H.; Mantovani, G.; Marks, D.; Mitch, W.; Muscaritoli, M.; Najand, A.; Ponikowski, P.; Fanelli, F.; Schambelan, M.; Schols, A.; Schuster, M.; Thomas, D.; et al.
	2008	Association of Sjögren's syndrome (SS) and systemic lupus erythematosus (SLE) with BLK	Cobb, B.; Kaufman, K.; Wang, Y.; Kelly, J.; Jonsson, R.; Bolstad, A.; Brun, J.; Rischmueller, M.; Lester, S.; Witte, T.; Mariette, X.; Kimberly, R.; Edberg, J.; Bae, S.; Jacob, C.; Alarcon-Riquelme, M.; Vyse, T.; Gilkeson, G.; Kamen, D.; Moser, K.; et al.